Daniel CF Ng 伍长辉’s Post

This Valentine’s Day let’s celebrate a different kind of connection – between science and progress.    Researchers are developing a new type of technology that could reshape cardiovascular drug development, offering a more efficient and ethical path forward.    Called Heart-on-a-Chip, the tech works by replicating intricate interactions of human heart cells. As we mark this day of love, let’s also applaud the dedication of scientists worldwide collaborating to advance healthcare solutions.    Check out the news story for more info on this technology: https://lnkd.in/g8HiyPWX    #ValentinesDay #Bioscience #Biomedicine #Nanotechnology

⚡️ Advanced imaging modalities to take pharmaceutical research to the next level 💡 Watching real time #drug responses in whole living animals, visualizing drug #delivery vehicles at #nanoscale level and removing the need to section #biopsies altogether could be a dream for many #researchers. This eliminates the need of preparing #histologically stained samples obtained hours after the drug administration. 📌 Intrinsically #fluorescent drugs (e.g. doxycycline, minocycline etc.) are easier to be characterized. By using a tunable #multiphoton #laser, by using near Infrared (#NIR) excitation, deeper #tissue characterization / visualization is possible while eliminating the need for tedious tissue sectioning. The same multiphoton #microscope (second harmonic generation, #SHG) can be used for label-free #imaging of large non-centrosymmetric structures such as collagen, microtubules and muscle myosin, which may serve as #biomarker for the drug’s efficacy. 💡 Visualizing drug effects in whole organs and small animals Techniques like spinning disk confocal, lightsheet and selective plane illumination microscopy (SPIM), enable researchers to see the #pharmacokinetics (PK) of a drug in real time and in-situ for macroscale characterization and monitoring system-wide drug effects of porous nanoparticles, lysosomes, PLGA-encapsulated drugs. Whether that be in a tissue construct, organoid or whole living animal - stage-top incubation systems allow to dynamically image large volumes of tissues and small animal models over the course of days with millisecond temporal. 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗿𝗲𝗮𝗱 1️⃣ Medical imaging plays very crucial role in healthcare space https://lnkd.in/ehkSR4u5 2️⃣ Bond-selective fluorescence imaging with single-molecule sensitivity https://lnkd.in/e7sjRZBX ©️ Inspired by the article “More than just a microscope: how advanced imaging modalities can take your pharmaceutical research to the next level” published in Drug Target Review on 05 Jul 2023 #DrugDevelopment #CellularImaging #DiagnosticImaging #FluorescenceImaging #PharmaInnovation

Precision Culture Scaling to Establish High-Throughput Vasculogenesis Models Nicholas R. Dennison, et al , Advanced Healthcare Materials 2024. Hydrogel-based 3D cell cultures can recapitulate (patho)physiological phenomena ex vivo. However, due to their complex multifactorial regulation, adapting these tissue and disease models for high-throughput screening workflows remains challenging. In this study, a new precision culture scaling (PCS-X) methodology combines statistical techniques (design of experiment and multiple linear regression) with automated, parallelized experiments and analyses to customize hydrogel-based vasculogenesis cultures using human umbilical vein endothelial cells and retinal microvascular endothelial cells. Variations of cell density, growth factor supplementation, and media composition are systematically explored to induce vasculogenesis in endothelial mono- and cocultures with mesenchymal stromal cells or retinal microvascular pericytes in 384-well plate formats. The developed cultures are shown to respond to vasculogenesis inhibitors in a compound- and dose-dependent manner, demonstrating the scope and power of PCS-X in creating parallelized tissue and disease models for drug discovery and individualized therapies. Full paper link: https://lnkd.in/e-DCFtJs Our product Links: hTert-Human Retinal MVECs: https://lnkd.in/evq5Mubi GFP-Human Retinal MVECs: https://lnkd.in/eQjt3WF hTert-Human Retinal MV Pericytes: https://lnkd.in/dBxWuxiu

🧬👩🔬 Are you aware that the sex of cells can make a difference in drug development and testing? In this article, published by the renowned international publication Forbes, Lisa Falco, a consultant in data, AI and FemTech, dives deep into this topic. She introduces the work of CSEM’s Samantha Paoletti and our Tools for Life Sciences team who are developing organ-on-chip devices that can mimic human physiology and response to drugs. These devices can help researchers understand how drugs affect men and women differently, for example how hormonal changes during the menstrual cycle can also influence drug reactions. 💊🩸 This read is for anyone interested in women’s health, personalized medicine, and innovation. 📰👉 Check it out here: https://lnkd.in/gMrwztm9 #FemTech #OrgansOnChip #OOC #PersonalizedMedicine #Innovation

The rapid advancement of nanomedicine presents novel alternatives that have the potential to transform health care. Targeted drug delivery as well as the synthesis of nanocarriers is a growing discipline that has been intensively researched to reduce the complexity of present medicines for a variety of diseases and to develop new treatment and diagnostic techniques. There are several designed nanomaterials used as a delivery system that deliver the drug moiety directly into its targeted body area, reducing the toxic effect of conventional drug delivery, reducing the amount of drug required for therapeutic efficacy, and offering many more advantages. Currently, these nanomaterials find application in diverse areas such as cancer treatment, contrast agents for imaging, biomarker detection, and more. To promote research on nanomedicine and its applications such as drug delivery, vaccine development, antibacterial diagnosis, diagnostic tools, imaging techniques, wearable devices, implants, high-throughput screening platforms, and many more, BTL Biotechno Labs Pvt. Ltd., in collaboration with its principal partner NanoCompsix, is offering a flat 50% off on all the Bioready Nanoparticles to the vibrant and dynamic Indian research community. Offer is valid till 30/9/2023. nanoComposix | Fortis Life Sciences Asanga Halangoda #lifescience #researchanddevelopment #biotechnology #pharmaceuticalcompany #nanoparticles #nanocarriers #vaccinedevelopment #drugdelivery #nanomedicines #bimarker #naobody #lateralflowassay #btlbiotechnolabspvtltd

North America Digital Pathology Growth Surges by 2028 Download Sample PDF Report-https://lnkd.in/d9gwkAvg The global digital pathology market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.8 billion by 2028, growing at a CAGR of 13.6% from 2023 to 2028. Companies Working in the Market Digital Pathology Association 3DHISTECH - The Digital Pathology Company Motic Digital Pathology PreciPoint - Advanced Digital Pathology Solutions Huron Digital Pathology Indica Labs OptraSCAN Visikol Reveal Biosciences CellCarta Tribun Health Source BioScience UnivLabs Technologies Pvt Ltd BioView MultiplexDX International Datexim TissueGnostics Cureline Group - Global Translational CRO Enspectra Health, Inc. PictorLabs Inc TELEMIS OracleBio National Pathology Imaging Co-operative (NPIC) Pathware Inc. Visia Lab Srl KFBIO BioImagene Lumito AB InnoSer aetherAI 雲象科技 Motic Europe HistoIndex

In Vitro Model for Analysis of High-Flow Aerosol Delivery During Continuous Nebulization https://bit.ly/45XfpGz

In Vitro Model for Analysis of High-Flow Aerosol Delivery During Continuous Nebulization https://bit.ly/45XfpGz

Intrigued about natural health solutions? Watch this short video to learn more about Biological Medicine and what types of modalities we are using at Vitality BioMed.

North America Digital Pathology Growth Surges by 2028 Download Sample PDF Report-https://lnkd.in/dMkFfMyv The global digital pathology market in terms of revenue was estimated to be worth $0.9 billion in 2023 and is poised to reach $1.8 billion by 2028, growing at a CAGR of 13.6% from 2023 to 2028. Companies Working in the Market Digital Pathology Association     3DHISTECH - The Digital Pathology Company Motic Digital Pathology PreciPoint - Advanced Digital Pathology Solutions      Huron Digital Pathology      Indica Labs   OptraSCAN Visikol   Reveal Biosciences CellCarta Tribun Health  Source BioScience   UnivLabs Technologies Pvt Ltd BioView    MultiplexDX International Datexim  TissueGnostics      Cureline Group - Global Translational CRO   Enspectra Health, Inc.      PictorLabs Inc TELEMIS  OracleBio National Pathology Imaging Co-operative (NPIC)      Pathware Inc.  Visia Lab Srl    KFBIO BioImagene    Lumito AB InnoSer      aetherAI 雲象科技   Motic Europe HistoIndex